Jana Schnaubert (Ulm/ DE), Dr. Peter Reinhardt (Ulm/ DE), Dr. Peter Schauwecker (Ulm/ DE), PD Dr. Daniel Fürst (Ulm/ DE), Dr. Alexandra Ulrich (Ulm/ DE), Dr. Astrid Marx-Hofmann (Ulm/ DE), Daniel Kefalas (Ulm/ DE), Dr. Elisa Sala (Ulm/ DE), Prof. Dr. Ansgar Schulz (Ulm/ DE), Prof. Donald Bunjes (Ulm/ DE), Dr. Markus Wiesneth (Ulm/ DE), Prof. Dr. Hubert Schrezenmeier (Ulm/ DE), Dr. Sixten Körper (Ulm/ DE)
Background
The yield of CD34+ cells obtained by apheresis (HPC-A) crucially depends on the success of CD34+ cell mobilization in combination with the efficiency of CD34+ cell collection. The collection efficiency 2 (CE2) describes the collection process under the assumption of a steady state of CD34+ cell count in peripheral blood throughout the whole procedure. We state the hypothesis that the capacity to maintain the steady state varies between different donors.
Methods
All HPC-A procedures between 27AUG2009 and 14APR2023 were extracted from our electronic records (n=5780, autologous: n=1922, allogeneic: n=3858). HPC-A was performed with the Cobe Spectra or the Spectra Optia. Patients were usually mobilized with G-CSF and chemotherapy. Plerixafor could be used in addition for poor mobilizers. Allogeneic donors were mobilized with G-CSF alone. As the collection efficiency 1 cannot always be calculated from routine data, in addition to CE2 we introduced a process efficiency (PE) calculated by (Number of collected CD34+ cells/ (total blood volume[l] *CD34+ in peripheral blood [cells/l])*100%. Data is given as mean ± S.D.. A Mann-Whitney test was used to test for significance.
Results
CE2 was higher in allogenic than autologous HPC-As (62±34% vs. 58±25%). Using the Spectra Optia the difference was 69±38% (allogenic, n=2727) vs. 58±24% (autologous, n = 1434). Males had higher CE2 in allogeneic (63±38% vs. 60±25%) and autologous HPC-As (60±27% vs. 56±19%). CE2 was slightly higher in multiple myeloma (MM) patients than in other lymphomas (60±20% vs. 57±34). PE was higher in allogeneic than in autologous HPC-As (142±60% vs. 136±70%). There was no difference between MM and lymphoma patients (134±62% vs. 135±81%). For all differences p< 0.001. Linear regressions showed a slight decrease of CE2 on the processed blood volume (PBV) (-2.8%/PBV). PE increased with PBV (58.4%/PBV) or time (0.55%/min).
Conclusion
Different parameters contribute to the success of HPC-A: gender, allogeneic and autologous collection as well as the type of disease influence the effiency of CD34+ cell collection. Multivariate analysis will be provided to better characterize the contributing properties to HPC-A.
Offenlegung Interessenkonflikt:
none